Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Core Viewpoint - Karyopharm Therapeutics Inc. is set to report its first quarter 2025 financial results on May 12, 2025, and will host a conference call to discuss these results and other updates [1]. Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly through oral compounds that address nuclear export dysregulation, a key mechanism in cancer development [3]. - The company's lead product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor that has received approval in the U.S. for three oncology indications and has also been approved in various international markets, including Europe and China [3]. - Karyopharm has a focused pipeline targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3].